MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Tuesday, January 7, 2025 1 min read

Key Takeaway: MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Full Press Release Details

MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia.